Imaging study reveals rapid formation of Alzheimer's-associated plaques

The amyloid plaques found in the brains of Alzheimer’s disease patients may form much more rapidly than previously expected. Using an advanced microscopic imaging technique to examine brain tissue in mouse models of the devastating neurological disorder, researchers from the MassGeneral Institute for Neurodegenerative Disease (MGH-MIND), working with colleagues from Washington University School of Medicine, find that plaques can develop in as little as a day and that Alzheimer’s-associated neuronal changes appear soon afterwards. Their report will appear in the Feb. 7 issue of Nature.

“While we’ve known for a long time what amyloid plaques and other changes seen in the brains of Alzheimer’s patients look like, we didn’t know in what order and at what speed those changes occur,” says Bradley Hyman, MD, PhD, director of the Alzheimer’s Unit at MGH-MIND and senior author of the Nature paper. “Understanding the rules that govern plaque formation may lead us to ideas about how to intervene in the process.”

To investigate the timing of these brain changes, the researchers used a novel technique for microscopically imaging the brains of living animals. Using several strains of transgenic mice destined to develop amyloid plaques, they imaged initially plaque-free areas of the brain on a regular basis – first weekly and, in subsequent experiments, daily. Although plaques formed rarely, they could appear as little as 24 hours after a previous plaque-free image was taken. The new plaques were similar in appearance to those seen in the brains of Alzheimer’s patients and in the mouse models, and subsequent imaging showed little change in the size of plaques once they had formed.

Earlier investigations have shown that levels of microglia – neuronal support cells that react to inflammation and other damage – rise in the vicinity of amyloid plaques. Imaging an Alzheimer’s mouse model that expresses a fluorescent marker in microglia showed that the cells were attracted to new plaques within a day of formation. Although there was no evidence that microglia were actively removing the plaques, the investigators hypothesize that they may help restrict further plaque growth. Examining neurons adjacent to plaques showed that the kind of changes associated with Alzheimer’s – distortions in the projections through which neuronal signals pass – appear rapidly and approach maximum effect within five days.

“These results confirm the suspicion we’ve had that plaques are a primary event in the glial and neuronal changes that underlie Alzheimer’s dementia,” Hyman says. “We hope that what we’ve learned about the time frame and sequence of events will help us find ways to keep plaques from forming.” Hyman is the John Penny Professor of Neurology at Harvard Medical School.

Source: Massachusetts General Hospital

Related stories:

Scientists Seek to Block Progression of Alzheimer’s Disease with Novel Medication that Targets the Source
(PhysOrg.com) -- Researchers at the University of California, San Diego Shiley-Marcos Alzheimer’s Research Center (ADRC) are conducting studies on an experimental medication to block nerve damage and inflammation in the brain that can lead to progressive memory loss and behavioral changes in people with Alzheimer’s disease. While current Alzheimer’s disease therapies focus on improving symptoms, this study aims to attack the root of the disease progression. Nationwide, 400 volunteers with mild to moderate Alzheimer’s disease are needed to further test this new approach.
Brain imaging study supports the 'cognitive reserve' hypothesis
Individuals with higher education levels appear to score higher on cognitive tests despite having evidence of brain plaques associated with Alzheimer's disease, according to a report in the November issue of Archives of Neurology.
Pittsburgh Compound B finds Alzheimer's-associated plaques in symptom-free older adults
In the largest study of its kind, Pittsburgh Compound B, an imaging agent that could facilitate the early diagnosis of Alzheimer's disease, has been used to identify amyloid deposition in the brains of clinically older adults.
A high-fat diet could promote the development of Alzheimer's
A team of Université Laval researchers has shown that the main neurological markers for Alzheimer's disease are exacerbated in the brains of mice fed a diet rich in animal fat and poor in omega-3s. Details of the study—which suggests that diets typical of most industrialized countries promote the development of Alzheimer's—are outlined in the latest online edition of Neurobiology of Aging.
Common epilepsy drug could prevent and treat Alzheimer's disease
The team led by UBC Psychiatry Prof. Weihong Song, who is also the Jack Brown and Family Professor and Chair in Alzheimer's Disease at UBC, found that if Valproic Acid (VPA) is used as a treatment in early stages of AD memory deficit is reversed.
New Membrane Model May Unlock Secrets of Early-Stage Alzheimer's
Researchers at the National Institute of Standards and Technology and three collaborating institutions are using a new laboratory model of the membrane surrounding neurons in the brain to study how a protein long suspected of a role in early-stage Alzheimer’s disease actually impairs a neuron’s structure and function. The team’s findings are reported in a new paper in the Biophysical Journal.
Scientists demonstrate means of reducing Alzheimer's-like plaques in fly brain
Neuroscientists at Cold Spring Harbor Laboratory (CSHL) are part of a collaboration that has succeeded in demonstrating that overexpression of an enzyme in the brain can reduce telltale deposits causally linked with Alzheimer's disease.
Study identifies toxic key to Alzheimer’s disease memory loss
Using new scientific techniques, scientists have unlocked the cascade of molecular events that lead to Alzheimer’s disease. The scientific findings published in the latest edition of Nature Medicine suggest a potential new target for the development of drug therapies to fight the irreversible and degenerative disease which affects some 29.8 million people worldwide. The total worldwide societal cost of dementia was estimated at somewhere in the region of US$315.4 billion in 2005.

News discussion:

Medicine & Health news